ライフサイエンスコーパス: angiotensin receptor

1 cal angiotensin II production and the type 2 angiotensin receptor.

2 asoconstriction via the activation of type 1 angiotensin receptors.

3 ing from elevated angiotensin II (AngII) and angiotensin receptor 2 (AT2R) producing increased plasma

4 1)-AA), stimulates sEng production via AT(1) angiotensin receptor activation in pregnant mice but not

5 covered that a circulating autoantibody, the angiotensin receptor agonistic autoantibody (AT(1)-AA),

6 onism of MAS1 receptors, beta-arrestin-based Angiotensin receptor agonists, and administration of sol

7 c administration of specific blockers of the angiotensin receptor and the Na-Ca exchanger.

8 embranes, which is distinctly different from angiotensin receptors and key proteases processing angio

9 colleagues present evidence that implicates angiotensin receptors and the relocation of beta-catenin

10 tural basis of the distinct functions of the angiotensin receptors, and may guide the design of new s

11 f angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist (88.3% versus 86.6%), an

12 Thus, this combined angiotensin receptor antagonist and neprilysin inhibitor

13 ll three isoforms of TGF-beta), losartan (an angiotensin receptor antagonist), or a combination of th

14 tumor's inner core, AD was combined with an angiotensin receptor antagonist, Telmisartan (TS), which

15 Heart Failure) trial demonstrated that a new angiotensin receptor antagonist-neprilysin inhibitor was

16 ay lead to the development of a new class of angiotensin receptor antagonists with activities biased

17 rs, calcium channel blockers, diuretics, and angiotensin receptor antagonists), smoking status, alcoh

18 of angiotensin-converting enzyme inhibitors/angiotensin receptor antagonists, use of beta-blocker, a

19 Here, we show that the angiotensin-receptor-associated protein (ATRAP) localize

20 Recently angiotensin receptor AT(2)R has been associated negative

21 n and termination of signaling of the type I angiotensin receptor (AT(1)-R) can lead to dynamic chang

22 genic autoantibodies that activate the major angiotensin receptor, AT(1).

23 Biased agonism on the type I angiotensin receptor (AT1-R) can achieve different outco

24 of beta-arrestins in cross-talk between the angiotensin receptor (AT1aR) and a member of the transie

25 beta-arrestin2 recruitment to unliganded AT1 angiotensin receptor (AT1R).

26 Using an angiotensin receptor bacterial artificial chromosome (BA

27 Angiotensin receptor blockade and inhibition of local An

28 odocytes, which was prevented by concomitant angiotensin receptor blockade application and TRPC6 knoc

29 hat inhibition of TGF-beta signaling through angiotensin receptor blockade can attenuate CS-induced l

30 ly, the addition of neprilysin inhibition to angiotensin receptor blockade has been shown to be even

31 erglycemia and the antiproteinuric effect of angiotensin receptor blockade or angiotensin-converting

32 injections (RR 0.45; 95% CI 0.24-0.83), and angiotensin receptor blockade vs placebo (RR 0.65; 95% C

33 egradation inhibition through neprilysin and angiotensin receptor blockade, has led to groundbreaking

34 to pharmacological reduction of fibrosis by angiotensin receptor blockade.

35 These effects did not depend on angiotensin receptor blockade.

36 mucociliary dysfunction, independent of its angiotensin receptor blockade.

37 combination therapy with NEP-inhibitors and angiotensin-receptor-blockade, which has been shown bein

38 otensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) affected the results.

39 ]: 1.04 to 1.10) and discharge ACE inhibitor/angiotensin receptor blocker (ARB) in LV dysfunction (64

40 tensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease ou

41 comparable antihypertensive activity to the angiotensin receptor blocker (ARB) losartan.

42 The combination of a diuretic and an angiotensin receptor blocker (ARB) or angiotensin-conver

43 ology study uses claims data to characterize angiotensin receptor blocker (ARB) prescription trends t

44 ensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) should be used for se

45 ed in increased cancer risk, with a focus on angiotensin receptor blocker (ARB) therapy, as recent pu

46 giotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortality in

47 otensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) use, ESA use, dialysi

48 sing angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (beta=0.36, P<0.001; CI: 0.

49 LCZ696, which consists of an angiotensin receptor blocker (valsartan [VAL]) and a nep

50 : high dose, 0.55; low dose, 0.72; both ACEi/angiotensin receptor blocker and beta-blocker: high dose

51 We hypothesized that angiotensin receptor blocker and neprilysin inhibitor, s

52 ate, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and oral anti-diabetic agen

53 Telmisartan, an angiotensin receptor blocker and partial PPAR-gamma agon

54 angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker as foundational therapy, wi

55 g angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy.

56 The angiotensin receptor blocker component of LCZ696, valsar

57 angiotensin-converting enzyme inhibitor and angiotensin receptor blocker groups resulted in two simi

58 ted, whereas acute HF and patients receiving angiotensin receptor blocker had higher plasma Ang II wi

59 been demonstrated that Valsartan (Val) as an angiotensin receptor blocker has renoprotective effects,

60 (angiotensin-converting enzyme) inhibitor or angiotensin receptor blocker if left ventricular ejectio

61 r angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in eligible patients.

62 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in persons with CKD to impr

63 Treatment for 4 weeks with the angiotensin receptor blocker irbesartan, but not with th

64 Providing the anti-fibrotic angiotensin receptor blocker losartan to mice in drinkin

65 The angiotensin receptor blocker losartan was given to half

66 Combined angiotensin receptor blocker neprilysin inhibitors (ARNI

67 giotensin receptor neprilysin inhibitor with angiotensin receptor blocker on Management Of heart fail

68 ting the renoprotective benefit of adding an angiotensin receptor blocker or a mineralocorticoid rece

69 eive angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy (P<0.01).

70 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 100% beta-blocker

71 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 35% beta-blocker t

72 d angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 51% beta-blocker t

73 n angiotensin-converting enzyme inhibitor or angiotensin receptor blocker throughout the study.

74 Angiotensin receptor blocker treatment may blunt the har

75 of associations and to explore the impact of angiotensin receptor blocker treatment.

76 nd to identify patients who can benefit from angiotensin receptor blocker treatment.

77 us, and has less advanced disease than prior angiotensin receptor blocker trials in HCM.

78 Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker uptake increased from 46% t

79 r angiotensin-converting enzyme inhibitor or angiotensin receptor blocker usage during continuous flo

80 d angiotensin converting enzyme inhibitor or angiotensin receptor blocker usage were not significantl

81 .5%, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in 24.9+/-1.9%, and asp

82 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in patients with an Ame

83 s in angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use or anticoagulation for

84 , angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and nonsmoking status-

85 Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, beta-blocker use, anti

86 angiotensin-converting enzyme inhibitor use, angiotensin receptor blocker use, BMI z-score for age an

87 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use-is well suited to provi

88 rketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysi

89 RNi with neprilysin inhibitor sacubitril and angiotensin receptor blocker valsartan on myocardial rem

90 loped by scientists at Novartis, combines an angiotensin receptor blocker with a neprilysin inhibitor

91 angiotensin converting enzyme inhibitor, and angiotensin receptor blocker), and N-terminal probrain n

92 nsin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally t

93 tensin-converting enzyme inhibitor (ACEi, or angiotensin receptor blocker), beta-blocker, or both dru

94 f an angiotensin converting enzyme inhibitor/angiotensin receptor blocker, and hydrochlorothiazide 12

95 for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralo

96 ent (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralo

97 n patients receiving higher doses of ACEi or angiotensin receptor blocker, beta-blocker, or both (haz

98 an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, o

99 DMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or beta-blocker) at baseli

100 ngiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, should generally be includ

101 Angiotensin receptor blocker-neprilysin inhibitor (ARNi)

102 n either stand-alone neprilysin inhibitor or angiotensin receptor blocker.

103 and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.

104 f angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

105 c agent that combines a NEP inhibitor and an angiotensin receptor blocker.

106 rd ratio for eplerenone versus placebo, ACEi/angiotensin receptor blocker: high dose, 0.67; low dose,

107 sin Receptor-Neprilysin Inhibitor] with ARB [Angiotensin Receptor Blocker] Global Outcomes in HFpEF),

108 tly less likely after dual treatment with an angiotensin-receptor blocker (ARB) and an angiotensin-co

109 erting-enzyme inhibitor (lisinopril) plus an angiotensin-receptor blocker (telmisartan) or lisinopril

110 st orally active direct renin inhibitor, the angiotensin-receptor blocker losartan, and their combina

111 scle fibrosis and improved pain Losartan, an angiotensin-receptor blocker with anti-fibrotic abilitie

112 in-converting enzyme inhibitor) or losartan (angiotensin-receptor blocker) in FSGS mice stimulated th

113 ngiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker.

114 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (18.2% vs 16.9%, p = 1.000

115 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (66% versus 68%; P=0.04) a

116 and angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) in acute myocar

117 ic shock, and mortality than those receiving angiotensin receptor blockers (all p < 0.001).

118 Pre-hospital use vs. non-use of angiotensin receptor blockers (aOR 2.02, CI 1.03-3.96) a

119 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are generally well t

120 nsin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) doses on outcomes in

121 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) initiated after myoc

122 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) were associated with

123 otensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blockers (BB),

124 ensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).

125 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and beta blockers.

126 nin angiotensin system pathways suggest that angiotensin receptor blockers (ARBs) are ideal drugs to

127 nsin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are widely prescrib

128 sin-converting-enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) both increased sign

129 Angiotensin receptor blockers (ARBs) convert myofibrobla

130 The use of angiotensin receptor blockers (ARBs) correlates with red

131 ertensive patients (n = 469), patients using angiotensin receptor blockers (ARBs) did not show a decl

132 PURPOSE OF REVIEW: As their introduction, angiotensin receptor blockers (ARBs) have been widely pr

133 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with ty

134 has revealed that ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be beneficial i

135 sin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) may increase the ri

136 otensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) may make patients m

137 in-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on the composite of

138 iotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (

139 iotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, and

140 otensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), beta-blockers, and

141 target the renin angiotensin system, such as angiotensin receptor blockers (ARBs), have been associat

142 in-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs), may be associated

143 tensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).

144 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (HR, 0.90; 95% CI, 0.79-1.

145 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ie, renin-angiotensin sys

146 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartil

147 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (p = 0.029), higher biliru

148 ile lower ATP was associated with the use of angiotensin receptor blockers (P=0.015).

149 tensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and beta-blockers

150 nsin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and cilostazol) an

151 iotensin-converting enzyme inhibitors and/or angiotensin receptor blockers achieves only partial reno

152 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 82% were receiving bet

153 expression is ameliorated by antiproteinuric angiotensin receptor blockers and angiotensin-converting

154 ith angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers and an o

155 use angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers compared

156 Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers were pre

157 Angiotensin receptor blockers are renoprotective in hype

158 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers at admission), beta-blocke

159 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers at discharge decreased in

160 and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers decreased from 89%, 84.9%,

161 f angiotensin-convering enzyme inhibitors or angiotensin receptor blockers during the study and a his

162 cardiovascular examples, such as the use of angiotensin receptor blockers for chronic heart failure,

163 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for more than 90 days betw

164 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for secondary prevention a

165 (3) angiotensin-converting enzyme inhibitor/angiotensin receptor blockers for systolic dysfunction,

166 he therapeutic benefits of beta-blockers and angiotensin receptor blockers given the emerging concept

167 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have demonstrated benefici

168 Thiazide diuretics, ACE-inhibitors or angiotensin receptor blockers if ACE-inhibitor-intoleran

169 Six previous trials of angiotensin receptor blockers in HCM enrolled a median o

170 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.

171 ngiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with heart fai

172 ngiotensin-converting enzyme inhibitors, and angiotensin receptor blockers increased by 23%, 57%, 31%

173 ensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers increases the likelihood o

174 and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on outcome in patients wit

175 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk and outcomes o

176 he renin-angiotensin-aldosterone system with angiotensin receptor blockers or angiotensin-converting

177 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investiga

178 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confide

179 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers use, was similar between c

180 Chronic treatment with angiotensin receptor blockers was associated with better

181 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was indicated in 18.1% of

182 Angiotensin receptor blockers were associated with lower

183 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP an

184 ensin-converting enzyme) inhibitors or ARBs (angiotensin receptor blockers) with beta-blockers (BBs)

185 ing angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 4.5 million not recei

186 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aldosterone antagonis

187 aneurysmal disease, including beta-blockers, angiotensin receptor blockers, and angiotensin-convertin

188 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and beta-blockers, respec

189 s, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers, and diuretics.

190 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and more sunscreen use in

191 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and P2Y12 antagonists) re

192 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins after acute m

193 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins reduces cardi

194 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, antiplatelet drugs, beta-

195 used in the clinic AT(1)R antagonist drugs (angiotensin receptor blockers, ARBs, or sartans) at prev

196 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, aldosteron

197 of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, aldosteron

198 Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and aldost

199 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and dual a

200 ns, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and dual a

201 sed angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, and statin

202 (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, spironolac

203 s, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium c

204 le angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or both.

205 of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or sacubitril-valsartan.

206 rs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, P2Y12 inhibitors, and the

207 -blockers, angiotensin-converting inhibitors/angiotensin receptor blockers, statins, diabetic treatme

208 and -3.07 mm Hg (95% CI, -4.99 to -1.44) for angiotensin receptor blockers.

209 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

210 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

211 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

212 zyme, and synthesis of its inhibitors and of angiotensin receptor blockers.

213 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

214 angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers.

215 of the next generation of beta-blockers and angiotensin receptor blockers.

216 angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

217 rt and compare to previous trials evaluating angiotensin receptor blockers.

218 .87 per 100 person-years for those receiving angiotensin receptor blockers.

219 .31; 95% CI, 1.22-1.40) than those receiving angiotensin receptor blockers.

220 angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

221 (+) intake and angiotensin converting enzyme/angiotensin receptors blockers Rx.

222 ing angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, beta-blockers, and devic

223 (ACE) inhibitors (1.08, 1.02-1.15, p=0.008), angiotensin-receptor blockers (1.16, 1.07-1.25, p=0.0002

224 A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-con

225 Angiotensin-receptor blockers (ARBs) are a widely used d

226 Angiotensin-receptor blockers (ARBs) are effective treat

227 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinur

228 sin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in coronavirus dise

229 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical co

230 ensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) reduce cardiovascul

231 tensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) who filled brand-na

232 ensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), 3-hydroxy-3-methyl

233 tensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and beta blockers

234 iotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), beta blockers, and

235 allergic myocardial infarction, anaphylaxis, angiotensin-receptor blockers (ARBs), beta-adrenergic bl

236 recent analysis showing increased risk with angiotensin-receptor blockers (ARBs).

237 ean BP reduction 12.9/7.7 mm Hg; p < 0.003), angiotensin-receptor blockers (mean BP reduction 13.3/7.

238 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after SAVR for severe AS b

239 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after surgical aortic valv

240 (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and statins), and adverse

241 (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and statins), and adverse

242 angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with gr

243 ACE-inhibitors and angiotensin-receptor blockers remain excellent first lin

244 re angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, alpha-blockers, beta-bloc

245 irm the beneficial effect of ACE-inhibitors, angiotensin-receptor blockers, and diuretics and/or beta

246 of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta blockers, calcium-ch

247 ng angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, and minera

248 ween previous treatment with ACE inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-ch

249 ., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers,

250 angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

251 angiotensin-converting-enzyme inhibitors, or angiotensin-receptor blockers.

252 is of unproven value, even beta-blockers and angiotensin-receptor blockers.

253 angiotensin-converting enzyme inhibitors or angiotensin receptor blocking agents 85.3% versus 77.4%

254 ssociated with increased activation of brain angiotensin receptors, enhanced sympathetic nervous syst

255 sms for sexual dimorphism of regional aortic angiotensin receptor expression and AAA formation are un

256 Mice lacking AT(1) angiotensin receptors have an impaired capacity to conce

257 s indicate widespread up-regulation of brain angiotensin receptors in SHR.

258 e findings suggest that activation of type 1 angiotensin receptors in the glomerulus is sufficient to

259 ies suggest that hyperactivation of brain AT angiotensin receptors is a major pathophysiological fact

260 In murine systems, there is a second type 1 angiotensin receptor isoform, AT1B, and its expression i

261 that are being probed include, among others, angiotensin receptors, matrix metalloproteinases, integr

262 Angiotensin receptor neprilysin inhibition (ARNI) therap

263 e based on type 2 diabetes status, age, sex, angiotensin receptor neprilysin inhibitor (ARNI) treatme

264 icacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), in pat

265 eptide and left atrial size suggest that the angiotensin receptor neprilysin inhibitor LCZ696 may red

266 ioN fracTion (PARAMOUNT) trial, in which the angiotensin receptor neprilysin inhibitor LCZ696 reduced

267 ents with heart failure (HF) treated with an angiotensin receptor neprilysin inhibitor lived longer w

268 The angiotensin receptor neprilysin inhibitor sacubitril/val

269 The angiotensin receptor neprilysin inhibitor sacubitril/val

270 rtality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/val

271 on enrolled in the Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotens

272 Angiotensin receptor neprilysin inhibitors (ARNi), beyon

273 ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), beta-b

274 We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with en

275 randomized in the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiot

276 from PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotens

277 ence in the rate of mortality when comparing angiotensin receptor-neprilysin inhibitor+BB+mineralocor

278 c defibrillator+ACE inhibitor or ARB+BB, and angiotensin receptor-neprilysin inhibitor+BB+mineralocor

279 be treated with a beta-blocker and one of an angiotensin receptor-neprilysin inhibitor, angiotensin-c

280 Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morb

281 GM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ACEI [An

282 (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [An

283 PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [An

284 PARAGON-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ARB [Ang

285 alocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitors (ARNI), have

286 neralocorticoid receptor antagonists [MRAs], angiotensin receptor-neprilysin inhibitors [ARNIs], and

287 ive efficacy of pharmacological therapy with angiotensin receptor-neprilysin inhibitors and device th

288 or adverse outcomes in patients treated with angiotensin receptor-neprilysin inhibitors.

289 ening in the Prospective Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with ACEI (an

290 duced ejection fraction treatment with ARNI (angiotensin receptor/neprilysin inhibitor) therapy or le

291 ystems diacylglycerol produced during type 1 angiotensin receptor signaling can be converted to 2-ara

292 al mechanism for biased ligand action at the angiotensin receptor that can be exploited to rationally

293 th an animal model of PTSD and the selective angiotensin receptor type 1 (AT1) antagonist losartan, w

294 played decreased fibrosis in response to the angiotensin receptor type 1 blocker losartan showed decr

295 Use of losartan, an angiotensin receptor type 1 blocker used widely in the c

296 derlies increased placental HIF-1alpha in an angiotensin receptor type 1 receptor agonistic autoantib

297 sin I converting enzyme (ACE) inhibitors and angiotensin receptor type I (AT(1)R) antagonists.

298 eptors different from AT(1)R, in particular, angiotensin receptor type II (AT(2)R), resulting in biol

299 ACE2 together with angiotensin receptor types 1 and 2 and ACE2 are componen

300 ance between angiotensin II, which activates angiotensin receptor types 1 and 2, and angiotensin 1-7